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ABSTRACT 
 
 
  
 The purpose of this project was to examine the effects of technology on society, using 
stem cell research as an example.  Stem cell research is far more complex than most believe, so 
in this project the first two chapters discuss the many different types and variations of stem cells 
that exist as well as their applications.  The latter two chapters deal with the ethical issues that 
surround this ground breaking research, and the laws various countries have enacted to help 
control the technology.  By the end of this IQP, both authors concluded that stem cell research 
has tremendous potential, but must be performed in an ethical manner to minimize controversial 
issues.  The progression of this science has the capability to improve the lives of millions which 
simply cannot be ignored.   
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PROJECT OBJECTIVES 
 
 
 The objectives of this IQP project were to examine the topic of stem cells, and to discuss 
the effect of this controversial technology on society.  The purpose of chapter-1 is to describe the 
many different types of stem cells and their potencies, as well as document how they are isolated 
and classified.  Chapter-2’s purpose is to document the advantages and disadvantages of the 
varying types of stem cells, and discuss the potential applications stem cells could be used for.  
Chapter-3’s purpose is to examine the ethics that surround this controversial topic by describing 
the ethical position of five of the major world religions, while Chapter-4 examines the laws that 
the US and international countries have enacted to govern the use of stem cells.  Finally, a 
conclusion is made by the authors regarding the use of stem cells, and which laws best represent 
the author’s point of view. 
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Chapter-1: Stem Cell Types 
Bryan Choate 
 
 Over the past couple of decades, stem cell research has become a worldwide 
phenomenon, infiltrating many aspects of modern day society.  Medical research, political 
agendas, and religious disputes have all been influenced by stem cell technology.  But what 
makes this cell type so different from the plethora of other cell types present in a human body? 
What makes them so different from say a skin cell or a muscle cell found in the bicep of a 
person?  And to make things more complex, stem cells are not all alike.  To help understand the 
potential of stem cells and their controversies, this chapter provides a brief background on their 
types and potencies. 
 
General Stem Cell Characteristics 
 Two main characteristics define a stem cell: the ability to self-renew and the ability to 
differentiate into other tissues.  The capacity to self-renew refers to the ability of the stem cell to 
divide multiple times giving rise to more stem cells that all exhibit the same traits.  Some stem 
cell lines are so long lived, they last the lifetime of the individual.  Differentiation is the ability of 
a cell to change into specialized cells that constitute the fundamental make up of our tissues and 
organs (International Society, 2009).  Because stem cells have the ability to form new tissues, 
they have been focused on in the medical world.  “This unique quality of stem cells make them 
ideal for treating injury and disease by repairing or replacing damaged or diseased body cells 
with healthy new cells” (MedIndia.com, 2006).   
Many diseases or injuries can benefit from the implementation of stem cells.  One such 
example of this is a person who has experienced a myocardial infarction (heart attack), where the 
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blood supply has diminished in a heart vessel, causing tissue necrosis downstream.  But, by 
transplanting stem cells into the damaged area allowing them to differentiate and grow into new 
healthy tissue, there is the possibility that new myocardial muscle cells may develop regenerating 
and restoring function to the once damaged organ (MedIndia.com, 2006).  Examples like this, 
among others, are why stem cells have been heavily focused on in the world of medical research.  
But there is much more to stem cells than there appears, including multiple different types and 
potencies.  
 
Stem Cell Potencies 
 In the world of stem cells, there exist multiple types, each with their own unique 
characteristics that serve as advantages or disadvantages in a given situation.  Each of these stem 
cell types come from a different place in the body, or are formed at different points in 
development.  The four main types include embryonic stem cells, induced pluripotent cells, 
parthenogenetic embryonic stem cells, and adult stem cells.  Each of these various types will be 
explained in further detail below.  However, each cell type also has a different potency.  Potency 
refers to which cell types a given stem cell can differentiate into; the higher the potency, the 
greater number of tissues the cell can form. 
The highest level of potency is totipotency.  Totipotent cells have the ability to form all 
cells of an adult organism plus extra-embryonic tissues such as the placenta.  Only the newly 
fertilized zygotes through cells of the 8-cell stage are considered to be totipotent; i.e. cells 
through about 3 days post-fertilization (Types of Stem Cells, 2004).  The second tier of potency 
is pluripotent stem cells.  These cells can form all cells in the adult, but cannot form placenta.  
Embryonic stem cells, found in a day-5 blastocyst, are pluripotent.   The next level below 
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pluripotency is multipotency.  These cells have the potential to make several different cell types 
of related cells.  Examples of multipotent cells include mesenchymal stem cells which have the 
ability to differentiate into several different tissue types, and hematopoietic stem cells that can 
form all the cellular components of blood.  The lowest level of potency is unipotency.  As the 
prefix uni- suggests, this cell type only has the ability to differentiate into one type of cell, 
typically the tissue from which the stem cells was derived.  An example of this can be epithelial 
stem cells which appear to only be capable of making epithelial cells. 
 
Embryonic Stem Cells: 
 Embryonic stem (ES) cells are pluripotent cells derived from the 5-day old human 
embryo.  They are pluripotent and have the ability to differentiate into over two hundred 
different cell types that found in the body.  Egg and sperm cells are fertilized in vitro, and the 
zygote is grown about 5-days to the blastocyst stage.  The blastula consists of an inner cell mass 
(from which ES cells are obtained), and an outer trophoectoderm layer.  The ES cells are isolated 
from the inner cell mass, which usually destroys the embryo.  Once the cells are extracted from 
the inner cell mass, they can be grown into ES cell lines (International Society, 2009).  
Most of the embryos used for deriving ES cell lines were originally created for 
reproductive purposes at in vitro fertilization (IVF) clinics.  Once the family has enough 
children, the excess embryos are usually discarded, so clinics sometimes ask for donor consent to 
use the excess embryos for research.  ES cell lines were first isolated in 1981 from mice (Martin, 
1981) and from humans in 1998 (Thomson et al., 1998).  The ES cells are isolated from the inner 
cell mass of the blastocyst, and plated onto a feeder layer of irradiated mouse fibroblast cells that 
provides a sticky scaffold to which the human ES cells may attach and releases nutrients into the 
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culture medium that help stimulate growth (NIH, 2005).  If the ES cells continue to grow and 
divide, they crowd the original dish, and then they are split into other dishes.  If these newly 
transferred cells survive, the re-plating of the cells can be repeated as many times as needed to 
provide large numbers of cells for therapy.  The process in which the cycles of sub-culturing 
takes place is referred to as passaging.  
 
iPS Stem Cells 
 “Generating pluripotent stem cells directly from adult cells isolated from patients is one 
of the ultimate goals in regenerative medicine” (Yamanka, 2007), and over the past five years the 
most exciting cell type addressing this is the revolution of induced pluripotent stem (iPS) cells.  
In this process, an adult skin cell is directly reprogrammed by transcription factors to de-
differentiate the cell into a pluripotent cell.  The strategy of cellular reprogramming was first 
introduced and pioneered by Shinya Yamanaka of Kyoto University in Japan who first 
accomplished this in mice (Takahashi et al., 2006), then later in humans (Takahishi et al., 2007).  
Yamanaka’s group first used retroviruses to insert four genes encoding transcription factors 
Oct3, Sox2, c-Myc, and Klf4 into the chromosomes of mouse skin cells to induce their 
reprogramming (Aldhous, 2009).  Initially, 24 different potential factors were tested for their 
ability to induce pluripotency, which eventually lead to the identification of the four 
transcriptions factors mentioned above.  Later experiments used three factors, then two, and 
introduced the transcription factor proteins themselves instead of the genes to avoid genetic 
reprogramming.  But because viruses were used to deliver the genes, and in some cases tumors 
formed at the injection site, in later experiments viruses were eliminated along with the c-Myc 
oncogene component to minimize tumor formation (Aldhous, 2009).  
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 Yamanaka is also focusing making iPS cells by fusion between somatic cells and ES cells 
to produce a hybrid cell that is pluripotent by nature, although this process uses controversial ES 
cells.  His group is also working on packing the necessary genes into a “piggyBac” transposable 
element that ejects itself from the chromosomes upon reprogramming of the cell (Aldhous, 
2009).  These techniques offer exciting and fascinating new ways to reprogram generic somatic 
cells into pluripotent cells that might be used in lieu of ES cells to treat diseases.  
    
Parthenogenetic Embryonic Stem Cells 
 Parthenogenesis, “virgin birth”, is a biological process in nature which allows lower 
organisms such as reptiles and insects to initiate embryonic development without a male 
counterpart.  This form of asexual reproduction has surprisingly become a promising source of 
ES cells.  Although parthenogenesis does not normally occur in mammals, mammalian eggs can 
be chemically treated to induce cell division without fertilization.  Once the treated embryo 
begins cell division, it can be grown to the blastocyst stage from which ES cells are obtained 
(Linzhao, 2008).  Even though ES cells can be isolated, the embryo is not capable of surviving 
more than a few days, so some scientists believe parthenote embryos are advantageous to 
fertilized embryos.  There is no chance that human parthenote embryos would develop into a 
human being, which might reduce their ethical concerns (Westphal, 2003).  
 Though the potential for this parthenogenetic technique is great, there are still many 
unknowns that might limit progress for parthenote-derived ES therapies.  An example of such a 
limitation would be the determination of the normality of the stem cells retrieved from a 
parthenogeneic embryo; since the parthenote cells are derived from one parent there is the 
possibility that these cells will be dangerously inbred which could lead to complications if used 
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in human patients (Weiss, 2001).  Other concerns focus on whether they are more prone to 
metastasize like tumor cells?  At this time there simply is not enough information to address 
these concerns, but in time and with further research perhaps these cells can be proved to be safe 
and effective.  
 
Adult Stem Cells 
 Within the many adult tissues of the body there exists a particular type of cell specific to 
each tissue type with the ability to replace cells in that tissue that have died or that can heal tissue 
after an injury.  These cells are referred to as adult stem cells (ASCs), which inhabit many areas 
of the body ranging from skin, to muscle, to bone marrow.  ASCs are either multi-potent or uni-
potent, so they can only differentiate into a limited number of mature cell types, usually the one 
tissue in which these stem cells reside.  ASCs are often very difficult to isolate due to their rarity 
(International Society…2009).  However, a few cell types such as hematopoietic or cardiac stem 
cells have allowed researchers to investigate this type of stem cell further. 
 
Hematopoietic Stem Cells 
 The most widely studied ASC is the hematopoietic stem cell (HSC).  These cells are 
found in bone marrow, but are also located in umbilical cord blood or peripheral blood.  
Traditionally, HSCs are isolated from the bone marrow and contain the ability to renew or to 
form all types of blood cells (white blood cells, red blood cells and platelets).  HSCs behave as 
normal white blood cells in culture, which makes isolating and growing them particularly 
difficult.  Instead of using morphology, scientists today try to identify HSCs by cell surface 
markers.  It is estimated that one in every 10,000 to 15,000 bone marrow cells are HSCs, and that 
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number jumps to one in 100,000 in the blood stream.  Even though HSCs are difficult to identify, 
scientists have determined that there exist two unique types: one with the ability to regenerate all 
types of blood cells, and the other with the potential to regenerate the bone marrow tissue itself 
over a span of a few months (Hematopoietic Stem Cells, 2005).  
 
Cardiac Stem Cells 
 Another very exciting discovery in the world of adult stem cells is cardiac stem cells 
(CSCs).  It was thought for decades that the heart could not repair itself by regenerating damaged 
tissue, and that the number of cardiac cells a person was born with was the number that person 
would have for the rest of their lives.  But recent studies have proven that the heart actually 
maintains a pool of cardiac stem cells that have the ability to differentiate into new cells if 
damage to the organ occurs.   
CSCs were first isolated as c-kit
+
 cells (Beltrami et al., 2003), and later as Isl1
+
 cells 
(Laugwitz et al., 2005).  Researchers have been able to isolate cardiac stem cells from the rat, 
and once cultured they were able inject those stem cells into rats with heart damage thereby 
regenerating 70% of the damaged myocardium within a 20 day period (Touchette, 2003).  
Similar cells have also been discovered in humans by researchers who were examining patients 
that had undergone cardiac surgery.  It appears that the stem cells had actually been trying to 
repair the damaged heart tissue, although usually insufficiently.  Now that these cells have been 
identified in humans, the next step is to learn how to mobilize them and stimulate their ability to 
grow and differentiate into new healthy cardiac tissue (Touchette, 2003).   
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Neural Stem Cells 
Like cardiac tissue, neurological tissue was once thought not to be able to regenerate after 
trauma or death.  However, in the mid 1990’s that idea would soon become irrelevant with the 
discovery of neural stem cells (NSCs).  During this time neuroscientists learned that particular 
parts of the adult human brain under certain conditions had the ability to generate and give rise to 
new neurons.  The most interesting part of this revelation was that these new neurons were 
formed from a neural stem cell that appeared to reside in a fetal state resembling cells in a fetus 
that form the brain and spinal cord (NIH, 2005).  Researchers also found that these 
undifferentiated cells were able to generate almost every type of cell in the human brain, 
including neurons, the main messenger carrier in the central nervous system (NIH, 2005).  
 
Mesenchymal Stem Cells 
 Within the adult stem cell universe there exists yet another type with immense potential, 
mesenchymal stem cells (MSC).  Unlike most ASCs, MSCs are relatively easy to isolate, culture, 
and manipulate in in vitro environments (Nardi and Meirelles, 2006).  These cells have great 
potential when it comes to therapeutic applications due to their plasticity; however, most of their 
properties are not fully understood.  MSCs are located in bone marrow and many other tissues.  
They are usually identified by a combination of their physical, phenotypic, and functional 
properties (Nardi and Meirelles, 2006).  Most of our knowledge derived from MSCs comes from 
in vitro studies where millions of MSCs have been cultured.  Due to the great potential that 
MSCs have when it comes to replacing damaged tissues like bone, cartilage, tendon, and 
ligament, MSC research will continue until their properties and location are fully understood 
(Nardi and Meirelles, 2006). 
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Chapter-2:  Stem Cell Applications 
Rebecca Paz 
 
   Recent advances in stem cell (SC) research have increased our understanding of cellular 
differentiation and human development.  Their potential for self-renewal and differentiation into 
specific cell types has resulted in a great deal of enthusiasm for their current and potential 
applications in medicine to repair tissue or restore function.  The previous chapter introduced the 
reader to the various types and sources of stem cells, and provided a few examples of their uses.  
The purpose of this chapter is to expand on their uses providing detailed information on how 
stem cells are being used to treat a selected group of four main categories of diseases.   This 
information on stem cell medical benefits will serve as introductory material for subsequent 
discussions on ethics and legalities. 
Table-1 provides a brief summary of the information presented in Chapter-1 on stem cell 
types relative to their advantages and disadvantages.  This information helps scientists select the 
most suitable cell type(s) for a wide range of applications. 
 
Table-1: Advantages and Disadvantages of Different Stem Cell Types. 
STEM CELL TYPE ADVANTAGES DISADVANTAGES 
 
  Embryonic (ESCs)  
 
-Pluripotent 
-Relatively easy to isolate 
-Highly productive in culture 
-High capacity to integrate into host 
tissue 
 
-Immune rejection unless derived 
from patient as iPS cells. 
-Might differentiate into wrong cell 
type or induce tumors 
-Risk of contamination from 
required feeder layers 
-Ethical concerns from embryo 
sources  
-Tight government regulation 
 
 
  Adult (ASCs) 
 
-Multipotent or unipotent 
 
-Scarce and difficult to isolate 
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       -Mesenchymal stem cells    
                    (MSCs) 
 
 
 
 
 
 
      -Adipose-derived stem cells  
                    (ASCs) 
 
 
    -Induced pluripotent stem cells 
                   (iPSCs) 
-Less likely to induce immune 
reaction if autologous  
-May be stimulated by drugs 
-Fewer ethical concerns 
-Less government regulation 
  
 
 
-Easy in vitro isolation and 
expansion 
-Capacity to migrate to sites of 
tissue damage, inflammation and 
neoplasia 
-Reduced immune rejection 
 
 
-Secrete cytokines and growth 
factors 
-Reduced immune rejection 
 
-Likely pluripotent 
-No immune rejection: patient 
specific therapy 
-Easy harvesting and production 
with high yield 
 
-Grow slowly 
-Differentiate poorly in culture 
-Difficult to handle and produce in 
adequate amounts for 
transplantation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-Risk of cancer formation 
(Sources: Liras, 2010; Leeb et al., 2011; Daniele et al., 2011) 
 
 
According to Liras (2010) by the year 2010, stem cell therapy procedures used the 
following types of cells:  human embryonal stem cells (hESCs) 13%, fetal SCs 2%, umbilical 
cord SCs 10%, and adult SCs in 75% of the reported treatments.  The main strategies used in the 
clinical applications of SCs include the stimulation of endogenous SCs with growth factors, 
cytokines or secondary messengers, the direct administration of unaltered SCs, and the 
transplantation of SCs after in vitro culturing (Liras, 2010; Terskikh et al., 2006; Leeb et al., 
2011). Following are the most common clinical applications of SCs to date, including 
applications for hematologic disorders, cardiovascular and ischemic disorders, spinal cord injury 
and central nervous system disorders, and diabetes. 
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Hematologic Disorders: The Use of Hematopoietic Stem Cells (HSCs) 
   Hematopoietic stem cells (HSCs) are multipotent adult stem cells that can renew 
themselves and differentiate into all types of blood cells (white blood cells, red blood cells, and 
platelets).  HSCs are responsible for the highly complex process of hematopoiesis (blood 
formation), which allows the body to respond to events such as infections and bleeding.  HSCs 
were originally obtained from the bone marrow, but they are also present in the peripheral blood 
after stimulation with growth factors, and are present in relatively large quantities in umbilical 
cord blood (Hematopoietic Stem Cells, 2005).  Recently, HSCs have also been derived by the 
differentiation of human ES cells and from induced pluripotent stem cells (iPSCs) (Kaufman, 
2009).  Due to their accessibility, HSCs have been extensively studied in the research and 
clinical settings, and represent the best characterized of all stem cell types. 
   After World War II, there was an intense interest in the effect of radiation on the body.  
Initial experiments in animals after exposure to intense radiation showed that the decreased 
blood cell counts associated with radiation could be remedied by the infusion of bone marrow 
from healthy animals. Later studies led to the discovery of HSCs as the regenerating component 
of the bone marrow infusions, and to the realization of their potential medical uses.  Animal 
models of bone marrow transplantation were successful and were eventually followed by the first 
human bone marrow transplants (Thomas et al., 1957).  Most of the initial transplants in humans 
were not successful, due in part to a host of complications including graft rejection, graft-versus-
host disease (GVHD), disease relapse, and infections.  Better understanding of the biology of 
stem cells, improvements in the technology, availability of new drugs, and increased donor pools 
eventually led to better clinical results (Little and Storb, 2002).  Although hematopoietic stem 
cell transplants continue to be complicated and risky procedures, they are currently used to treat 
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a variety of hematologic malignancies like leukemia and lymphoma, to rescue the bone marrow 
after intense cancer chemotherapy, and to treat bone marrow failure and genetic disorders. A 
retrospective study conducted by the Worldwide Network for Blood and Bone Marrow showed 
that of 50,417 hematopoietic stem cell transplants performed worldwide in 2006, 54.5% were for 
lympho-proliferative disorders, 33.8% for leukemias, 5.8% for solid tumors, and 5.1% for non-
malignant conditions (Gratwohl et al., 2010).  
 
HSCs and Leukemia and Lymphoma 
   Leukemia and lymphoma result from the uncontrolled proliferation of blood cells.  The 
treatment for these disorders usually involves the destruction of the malignant cells and the HSCs 
that form them by chemotherapy and/or radiation therapy.  In some hematologic malignancies a 
hematopoietic stem cell transplant from a donor (allogeneic transplant) may be the treatment of 
choice. In these cases, the patient receives intense chemo and/or radiation therapy to kill the 
malignant cells and bone marrow prior to the transplant, then receives an intravenous infusion of 
the donor’s bone marrow or peripheral blood cells containing HSCs.  Peripheral blood 
transplants (from patients treated with growth hormones to stimulate release of HSCs into the 
blood) have the advantage of a less invasive extraction than bone marrow and yield a higher 
concentration of HSCs (Koca and Champlin, 2008).  In some instances, HSCs can be harvested 
from the patient and replanted after therapy (autologous transplant) avoiding immune rejection of 
transplanted extraneous cells, so long as the patient’s own HSCs are not cancerous.  
   These therapeutic approaches are not without risk. HSC transplants are often associated 
with serious complications, including infections, veno-occlusive disease (VOD) of the liver, 
GVHD, graft failure, and relapse. The patient’s immune system can be severely compromised by 
 19 
pre-transplant conditioning therapy and the immunosuppressive drugs used post-transplantation.  
Prophylactic antibacterial, antifungal, and antiviral medications are often used in an attempt to 
prevent infectious complications frequently encountered, and these can carry a high mortality. 
VOD of the liver is a poorly understood condition characterized by jaundice, abdominal pain, 
hepatomegaly, fluid retention and weight gain that may be seen in 20-50% of transplanted 
patients treated with chemotherapy and radiation. GVHD is a condition in which lymphocytes 
from the donor recognize foreign antigens in the host cells and mount an immunologic reaction 
against them, causing tissue destruction in different organs including dermatitis, hepatitis and 
enteritis. Prophylactic therapy with drugs that suppress the immune response reduces the 
incidence of GVHD.  Graft failure results from failure of the transplanted SCs to thrive, which 
may occur in association with disease relapse (Tabbara et al., 2002).  
 
HSC Rescue of Cancer Chemotherapy 
   The treatment of certain non-hematologic malignancies, such as breast carcinoma, 
depends on how advanced the disease is, and usually involves the removal of the tumor by 
surgery.  In advanced cases, high doses of chemotherapy and/or radiation therapy are used.  In 
addition to killing the tumor, the treatment causes the destruction of rapidly growing normal 
bone marrow cells, resulting in low blood counts and increased risk of infection and bleeding. In 
the 1980s, autologous stem cell transplants were used in patients with advanced cancer in an 
attempt to rescue the patient’s bone marrow cells after intense chemo or radiation therapy.  A 
recent study by the German Institute for Quality and Efficiency in Health Care (Autologous Stem 
Cell Transplant, 2009) reviewed 19 clinical trials involving autologous stem cell transplants in 
the treatment of advanced breast cancer, and concluded that compared to conventional 
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chemotherapy, autologous SCT can significantly extend clinical event-free survival, but may 
also give rise to severe complications (Peters et al., 2000).  Similar results have been found for 
autologous HSC transplants (HSCT) for neuroblastoma and other non-hematologic malignancies 
(Kremer, 2011).  Most importantly, the transplant’s graft-versus-tumor effect, in which an 
immunologic reaction of donor lymphocytes is mounted against molecules present in cells from 
the patient’s cancer cells, increases the anti-tumor effect (Takahashi et al., 2008) and can 
contribute to the overall elimination of malignant cell growth. 
 
HSCs and Hematologic Non-Malignant Disorders and Inborn Errors of Metabolism 
   The first successful allogeneic HSCT on a patient with severe combined 
immunodeficiency (SCID) was performed in 1968 (Sullivan et al., 2000).  SCID is a genetic 
disease that destroys a patient’s immune system leading to severe infections and early death.  
Since 1968, HSCT has been used to treat a variety of non-malignant blood disorders, including 
aplastic anemia, Wiskott-Aldrich syndrome, thalassemia, sickle cell disease, and storage diseases 
such as Hurler syndrome. The best results are obtained in young patients and those that have 
HLA-matched identical siblings. HSCT is potentially curative in these disorders, but can be 
associated with complications like GVHD and opportunistic infections. It is reserved for severe 
cases without alternative therapy (Sullivan et al., 2000; Neven et al., 2009).  In gene therapy, the 
patient’s HSC are isolated, genetically engineered to express a normal copy of the defective 
gene, and transplanted back to the patient. This technique has curative potential and has been 
successfully used to treat SCID (Malech et al., 1997; Cavazana-Calvo et al., 2000; Bordignon, 
2006).  Several ongoing clinical trials may shed some light in this promising technology 
(http://clinicaltrials.gov/).  
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Stem Cell Treatments of Cardiovascular and Ischemic Disorders 
Myocardial infarction is caused by the obstruction of the cardiac blood flow, resulting in 
necrosis and loss of heart muscle cells. Regeneration of the lost tissue by stem cell therapy has 
been the subject of multiple studies reviewed by: Laflamme et al., 2005; Christoforou and 
Gearhart, 2007; Reinecke et al., 2008.   The papers focus on the ability of the different types of 
SCs to differentiate into functional cardiac cells. 
 
Adult Stem Cell Treatments of Cardiovascular and Ischemic Disorders 
Hematopoietic Stem Cells: The use of HSCs in heart regeneration has been studied for a 
number of years, which is surprising given their primary role of replenishing blood cells, not 
heart cells. The results have been controversial. Initial studies in mice (Bitter et al., 1999) 
suggested that HSC from a bone marrow transplant differentiated into cardiac cells; however, 
later studies (Alvarez-Dolado et al., 2003) indicated that the HSC do not differentiate into heart 
cells, but rather fuse with them. Clinical trials involving the injection of bone marrow HSCs into 
the heart of post-infarcted patients have shown mixed results (Lunde et al., 2006; Schächinger et 
al., 2006; Assmus, 2006). Additional clinical studies are needed to clarify these discrepancies. 
 
Skeletal Muscle Stem Cells: Satellite cells (myoblasts), found in adult skeletal muscle, 
retain the ability to differentiate and regenerate skeletal muscle. Clinical studies in humans 
(Siminiak et al., 2004) that administered satellite cells to diseased hearts demonstrated some 
improvement in cardiac function, but other studies have shown that myoblasts found in skeletal 
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muscle do not differentiate into heart cells and instead retain their skeletal muscle characteristics 
(Reinecke et al., 2002). 
 
Endogenous Cardiac Stem Cells: Cells thought to represent true cardiac progenitors 
have been identified in the heart; these cells can self renew and can differentiate into cardiac 
cells. In vitro and animal studies have suggested they function in cardiac regeneration (Bearzi et 
al., 2007). Several clinical trials testing the effect of cardiac stem cells in regenerating cardiac 
muscle are currently being conducted, but the results are still pending (http://clinicaltrials.gov. 
NCT00474461, NCT00893360). 
 
Mesenchymal Stem Cells: These cells form the bone marrow framework, are able to 
differentiate into several cell types, and express growth factors and cytokines. They have been 
proposed as potential treatments for cardiac disorders (Jain et al., 2005), and some clinical 
studies in humans have shown promising results (Chen et al., 2004). Additional studies are 
needed to understand their mechanism of action. 
 
Embryonal Stem Cell Treatments of Cardiovascular and Ischemic Disorders 
Cardiac progenitor cells have been differentiated from mouse and human embryonal stem 
cells (ESCs), and have been used in vitro to study cardiac disease and cardiac response to drugs. 
Animal studies have shown that cardiac progenitor cells derived from ESCs have the capacity to 
differentiate into adult cardiac cells and engraft, but they are associated with in vivo 
complications such as immune rejection and the formation of tumors (Laflamme et al., 2005). A 
few studies involving human ESCs have been published (Laflamme and Murry, 2005) and have 
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shown their ability to engraft, but these human studies are complicated by the scarcity of ESCs, 
immune rejection by the host, the risk of tumor development, and ethical concerns. 
 
iPS Cell Treatments of Cardiovascular and Ischemic Disorders 
The discovery of induced pluripotent stem cells (iPSCs) that result from the genetic re-
programming of adult somatic cells (Takahashi, 2006; Takahashi et al., 2007) has revolutionized 
the field of stem cell research. iPS cells may offer the pluripotent advantages of human ESCs, 
but without the associated ethical concerns because embryos are not destroyed.  In addition, 
iPSCs provide the ability to use a patient’s own autologous cells, reducing the chance of 
rejection.  iPS cells have been shown to be capable of differentiation into cardiac lineages  
(Reinecke et al., 2008). Future animal and clinical studies are needed to explore the use of iPSCs 
in cardiac regeneration. 
 
Treatment of Neurological Disorders with Stem Cells 
Central nervous system (CNS) disorders, often caused by the seemingly irreversible loss 
of its cellular components, are some of the most devastating diseases in humans. Stem cell 
therapy may offer the opportunity for tissue regeneration.  The CNS has traditionally been seen 
as a terminally differentiated system, with no regenerating capability. Several studies, however, 
have demonstrated the persistence of neural stem cells (NSCs) in certain regions of the adult 
human brain (Eriksson et al., 1998; Pinkus et al., 1998). Studying the normal embryological 
development of the nervous system has enhanced our understanding of NSCs and the possible 
applications of stem cell therapy for these disorders.  
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NSCs are undifferentiated cells found in the embryonic neural tube that have the 
capabilities of self renewal and differentiation into the three major cell types of the CNS, 
neurons, astrocytes, and oligodendrocytes.  NSCs are identified by the expression of specific 
marker molecules and have also been found in the periventricular area of adult human brains 
(Okano, 2010).  In culture, NSCs are identified by their ability to form neurospheres.  Animal 
and human NSCs have been cultured and expanded in vitro in several studies (Lindvall and 
Kokaia, 2006; Okano, 2010). 
Some of the neurological disorders that may benefit from NSC therapy include acute 
lesions like spinal cord injury, and degenerative disorders like Parkinson’s disease, Huntington’s 
disease, Alzheimer’s disease, and Amyotrophic Lateral Sclerosis (ALS). Spinal cord injury is 
associated with a loss of neurons and glial cells, inflammation and demyelination (degeneration 
of the myelin “sheath” of a neuron), resulting in the loss of movement and sensation below the 
level of the lesion. Spinal cord injury treatment with stem cells has been an area of extensive 
research (Tewarie et al., 2009; Koch et al., 2009).  A study involving the transplant of 
oligodendrite  progenitor cell in rats showed improvement of functions, and suggests that such 
improvement may be in part the result of remyelination (Keirstead et al., 2005). Additional pre-
clinical studies are necessary to optimize this therapy. Some clinical trials are ongoing, primarily 
involving somatic stem cell transplantation, including hematopoietic stem cells and adipose-
derived stem cells (http://clinicaltrials.gov/ct2/home). 
Neurodegenerative disorders, like Parkinson’s, Huntington’s, Alzheimer’s, and ALS are 
characterized by a selective, gradual loss of neurons and or glial cells in particular areas of the 
CNS, consequently with a variety of clinical manifestations. Transplantation of stem cells into 
animal models has shown some functional improvement achieved by replacing lost neuron and 
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glial cells, inducing remyelination, and controlling the inflammatory response (Lindvall and 
Bjorklund, 2004; Lindvall and Kokaia, 2006; Lindvall and Kokaia, 2010). According to 
Lindvall, transplanted fetal dopaminergic cells were able to engraft, secrete dopamine, and 
improve symptoms, although the clinical outcomes of the patients were variable (Lindvall and 
Bjorklund, 2004).  Additional research studies are needed before these therapies become 
clinically available.  
 
Treatment of Diabetes with Stem Cells 
Type-I diabetes is caused by the reduction or the absence of the hormone insulin, while 
Type-II is caused by a lack of response to insulin.  Insulin is produced by the β-cells of the 
pancreas and stimulates the uptake of glucose from the blood into cells. Without insulin the 
resulting high levels of glucose in the blood can cause multiple medical complications. Diabetes 
can be temporarily controlled by the administration of exogenous insulin, but the only potential 
cure is offered by pancreatic transplantation or by cell therapy.  Recent advances in stem cell 
understanding and technology have suggested the use of pluripotent stem cells as a source of β-
cells (Mayhew and Wells, 2010).  Much of the research has concentrated on the process of 
differentiating the insulin-producing cells from stem cell progenitors (Kroon et al., 2008). The 
natural development of pancreatic human β-cells has been reproduced in vitro by stimulating 
embryonal stem cells with transcription factors, cytokines and other small molecules to 
differentiate them into functional mature β-cells (Phillips et al., 2007; Kroon et al., 2008; Evans-
Molina et al., 2009; Mayhew and Wells, 2010). 
Most of the initial studies used ESCs as a source of pluripotent stem cells. More recently, 
iPSCs have been shown to offer several advantages over ESCs, including the ability to use 
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patient-specific cells, avoiding the need for immunosuppression, and fewer ethical and 
regulatory issues. Recent studies have demonstrated the ability to generate in vitro insulin 
secreting cells from iPSCs derived from human and murine fibroblasts (Tateishi et al., 2008) and 
to control hyperglycemia in vivo (Alipio et al., 2010). Although technical obstacles remain, these 
studies offer hope that iPSCs can eventually provide a patient specific cure for diabetes. 
 
 
Other Clinical Applications for Stem Cells 
A recent search for clinical trials with stem at ClinicalTrials.gov shows a total of 3,273 
ongoing studies encompassing a wide variety of applications including those already stated, as 
well as for eye diseases, cartilage and liver regeneration, wound healing, autoimmune disorders, 
AIDS, and others (Bainbridge, 2008; Chun et al., 2010; Sellheyer and Krahl, 2010; Kitchen and 
Zack, 2011).  Stem cell therapy is still in its infancy and we are only beginning to understand its 
potential.  New applications will continue to emerge, but much research is needed before specific 
therapies are validated clinically in humans and gain widespread use. 
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Chapter-3: Stem Cell Ethics 
Bryan Choate 
 
 Although stem cells have been shown to save lives, and their potential to do so increases 
daily, a raging debate exists over whether stem cell research should continue.  The purpose of 
this chapter is to go beyond a discussion of stem cell technology to discuss this ethical debate.  
As a framework, the stances of the five major world religions on stem cells will be reviewed. 
 
Introduction to Stem Cell Ethics 
The stem cell debate arises from disagreements about when life begins and the status of 
the embryo, and unfortunately is also based on misconceptions that the general public as well as 
high ranking officials have.  Some of the many misconceptions popular among those against 
stem cell research include: stem cells can only come from embryos, embryonic stem (ES) cell 
research has the greatest promise, and every cell is somehow an embryo thus a human life 
(Pacholczyk, 2008).  But these are true misconceptions.  As discussed in Chapter-1, there are 
multiple sources of stem cells and not all of them destroy an embryo, such as adult stem cells 
(ASCs) and induced pluripotent stem (iPS) cells.  And these latter cells have been shown in 
recent years to show promise for treating some types of diseases.  In fact, more human lives have 
been saved at this point in time from adult stem cells (especially hematopoietic stem cells) than 
from embryonic stem cells (Pacholczk, 2008).  
 The main focus of the stem cell debate is the status of the human embryo.  Religions that 
believe life begins at conception argue that the 5-day old blastocyst (from which ES cells are 
obtained) have the same status as a living human being, so destroying it is murder.  Religions 
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that believe life or personhood begins much later, or that saving current lives outweighs the 
status of potential life, allow the use of an embryo.  So the debate focuses on a balancing act 
between the benefits to society versus the detriment to the embryo.  Although not everyone is 
convinced of the medical benefit of stem cells, most in the scientific community now have a 
fairly broad consensus on the benefits of stem cells for science and biomedicine, and the 
evidence increases daily on new applications.  Chapter-2 attempted to alleviate some 
misconceptions about their past medical achievements and promise.  On the other hand, there is 
the controversial issue of “killing” human embryos and when life begins (Devolder, 2005).  Is it 
murder to kill an embryo that has the potential to become life?  It can become human only if 
implanted back into the uterus and carried to birth.  Is it murder to destroy a hollow ball of cells 
to grow immortal cell lines that can save lives? 
 
Catholic Stance on Stem Cells    
 Of all the world’s major religions, the Catholic stance against ES cells is perhaps the best 
known (American Catholic Organization, 2006). The Catholic Church believes that life begins at 
conception, so destroying a 5-day old embryo (obviously post-conception) is murder.  President 
Bush, listening to his Catholic advisors, struck what he thought was a balance with them.  On 
August 9, 2001, President Bush announced to the nation that he would be supplying government 
funding only to institutions that conduct ES cell research on ES cell lines derived prior to 2001, 
and would not allow federal funding to be spent to derive new cell lines.  The embryos used to 
derive the previous cell lines had already been “murdered”, and could not be murdered twice, so 
he allowed funding their use.  Even given Bush’s nod to the church’s stance by banning federal 
funding for the destruction of new embryos, because he allowed private funding for this, his act 
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sent the Catholic Church into an uproar (Fastiggi, 2010) causing the U.S. Catholic Bishop Joseph 
A. Friorenza who is president of the U.S. Catholic Conference of Bishops to issue a statement 
deeming this action morally unacceptable saying that “The federal government, for the first time 
in history, will support research that relies on the destruction of some defenseless human beings 
for possible benefits to others” (American Catholic Organization, 2006).  Bishop Friorenza 
would continue to say “We hope and pray that President Bush will return to a principled stand 
against treating some human lives as nothing more than objects to be manipulated and destroyed 
for research purpose.  As we face a new century of powerful and sometimes even frightening 
advances in biotechnology, we must help ensure that our technical advances will serve rather 
than demean our very humanity” (American Catholic Organization, 2006).  
 Judging from statements like this, it is clear how the Catholic Church associates itself 
with embryonic stem cell research.  But, this is not to say the Church is against all forms of stem 
cell research.  In fact in 2006 Pope Benedict XVI released a statement endorsing adult stem cell 
research as a means to respect human life.  Speaking at a summer stem cell conference, Pope 
Benedict urged the Catholic scientific institutions to double their efforts to create a closer 
relationship with others working in the field to strive for a breakthrough [with adult stem cells] 
that could relieve the suffering of many human lives (Catholic Online, 2006 2008?).  The Church 
has always been there to help and cure suffering, so it was only fitting that Pope Benedict would 
endorse advancements in biotechnology to accomplish that goal, so long as no embryos are 
destroyed.  Though the Catholic Church draws ethical lines when it comes to the different forms 
of stem cell research, the fact that they are willing to back adult stem cells is a tremendous step 
in the right direction that could help increase funding for those cells, and save millions of lives.   
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Christian Stance on Stem Cells 
 Like the Catholic Church, the Christian Church generally maintains a pretty strict stance 
against embryonic stem cell research, although unlike the Catholic Church with its single 
spokesperson in the Pope, non-Catholic Christians have multiple spokespersons so this large 
religion has multiple opinions.  The Christian Church generally realizes the potential of this 
research and the lives that can be saved, but at what cost?  To answer that question Christians 
often look to the Holy Scriptures of the New and Old Testaments to try and decipher what their 
stance should be.  In the Scriptures it is clearly stated that life is God’s creation and his gift.  This 
view typically demands that members of the Body of Christ must reject any technology that 
destroys another human beings life, even if that technology seeks “good” in terms of the 
chronically ill or injured.  “In Christian theology the ends may never justify the means.  Rather, 
life in the womb or tragically, in the petri dish is always viewed as human life” (Fleishmann, 
2001).  Regardless of whether the embryo is growing inside a woman or being grown for a 
scientific purpose, the Christian Church generally believes that all embryos are human beings 
and to “deny this denies the witness of the Scriptures and the Faith of the Church” (Fleishman, 
2001).  
 However, not all Christians are against ES cell research.  Some churches hold a more 
balanced stance that the lives saved outweigh the status of a 5-day embryo.  Such churches 
include some Methodists and Episcopalians (Faithful Progressive, 2005). 
 
Jewish Stance on Stem Cells 
 Unlike the two Christian religions, when it comes to playing God the Jewish people strive 
to emulate God by saving lives, as long as it is according to God’s rules as expressed by 
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authentic Jewish legal mandate.  The idea of emulating God is a religious tradition of paramount 
importance, as that concept mandates the Jewish people to heal and provide medical relief 
wherever possible (Jakobovits, 2006).  According to Jewish Scripture, the two professions 
undertaken by God were to teach or to heal, and if that requires the microscopic manipulation of 
cells to relieve suffering, the Jewish people have fulfilled their obligation to God (Jakobovits, 
2006).   
This ideology especially encourages the advancement and implementation of stem cells 
from adult tissues, but when it comes to embryonic tissues that is where problems begin to arise.   
The view of an embryo in the Jewish religion is on par with the Christian religions but slightly 
different.  The Jewish people consider a fetus to be a full-fledged human in most situations, 
stating that one may not intentionally harm a fetus, and sanctions would be placed upon anyone 
that tries to deliberately cause a woman to have a miscarriage (Eisenberg, 2006).  However, an 
embryo is not a fetus, and IVF embryos do not reside within a woman, so the Jewish 
interpretation of this varies.  In some circumstances, if an embryo comes in conflict with an 
already born individual then that person take precedence over the embryo.  For example the only 
way an abortion may take place in the Jewish Faith is if the embryo inside the woman constitutes 
a danger to the survival of the woman, but even then the embryo would not be used for 
harvesting stem cells.  Even embryos before day 40 which are considered to be just water would 
not be aborted with the intent to just harvest stem cells (Jakobovits, 2006).  However, an IVF 
embryo that does not reside within a uterus, and is used prior to day 40 where it has the rights of 
water, appears to be acceptable to most in this faith, especially if those cells are used to save 
lives.  This is reflected in Israel’s flexible laws that allow ES cell research, along with other 
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countries such as Australia, Belgium, China, India, Japan, Singapore, South Korea, Sweden, and the 
United Kingdom (discussed in Chapter-4).   
 
Islam 
 Islam, like Judaism, shares strong traditions of legal and religious laws, including 
supporting most forms of stem cell research.  With respect to when Islam considers the embryo 
alive, and is it acceptable to destroy those embryos for the advancement of scientific research, 
chapter 23, verse 12-14 of the Qur’an (the major authority in Islam) depicts an image of the 
creation of man starting from a clot and developing into tissue, then bones, and finally another 
creature.  This passage has been interpreted to indicate that the fetus is considered a human life 
only after about the fourth month of pregnancy (Weckerly, 2002).   Since the fetus is not 
considered to be alive until about 120 days after fertilization, most interpretations of Islamic law 
suggest that an embryo is not considered to be a person, so to use an embryo for scientific 
research does not violate any law in the Islamic society (Weckerly, 2002).  Moreover, since the 
embryo is not in its natural environment and is not going to be placed in the womb, it will not 
survive and become a human, so most agree that the Islamic religion finds nothing wrong with 
conducting this kind of research, especially if it has the potential to cure disease and stop the 
needless suffering of individuals (Sachedina, 2000).  
 
Buddhism and Hinduism 
 Like so many other religions, the Buddhist religion considers medical research as 
valuable, as long as it is intended to help others.  So Buddhists tend to approve of adult stem cell 
research, but when it comes to fetal stem cell research it it quite the opposite.  According to 
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Buddhism, the embryo is considered life, and to destroy it would go against everything they 
believe in as Buddhists place a great importance on the principle of non-harming life; therefore 
embryonic stem cell research would not be permitted (Holmes, 2004).  Although, when it comes 
to aborted fetuses, some believe that since life is already deceased it is permissible to harvest 
stem cells from the aborted fetus (Keown, 2004).  But the other side says the action of abortion 
itself is tainted by immorality, so the cells should not be harvested due to that fact alone (Keown, 
2004).    
 The Hindu religion believes that all life is scared including animal and plant life.  The 
heart of the Hindu doctrine is to live a life of non-violence and respect every living creature that 
inhabits this land by showing love to all things.  Though to survive humans must kill those 
animals and plants for food, the religion focuses mainly on preserving the highest level of 
consciousness possible (Bahnot, 2008).  Hindus believe the soul passes through as many as 8.4 
million species before it reaches the highest level of consciousness reborn as a human.   Thus, 
human life is much more valuable than an embryonic cell that has not reached full 
consciousness, so it becomes permissible to sacrifice a few cells for the greater good of saving 
already reincarnated humans (Bahnot, 2008).   
 
iPS Cell Ethics 
 The hottest topic in stem cell research today is that on induced pluripotent stem (iPS) 
cells.  Unlike ES cells that destroy an embryo, iPS cells are derived from a generic skin cell from 
a donor and reprogrammed to have similar pluripotent capabilities.  Although their potency is 
still being debated and investigated, some scientists believe iPS cells can be stimulated to 
differentiate into many different cell types (Brind’Amour, 2009).  Because they destroy no 
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embryos, and appear to be pluripotent, the promise of these iPS cells is immense.  Initially, 
retroviruses were used to transform the fibroblast cells, but the resulting cells sometimes 
developed tumors, so now the transformation is performed directly by adding the reprogramming 
proteins themselves not by viruses delivering the genes (Brind’Amour, 2009).   
 If iPS cells are shown in experiments to be truly pluripotent, they could seemingly 
replace embryonic research all together.  The fact that numerous laboratories have been able to 
reproduce iPS cells independently is a testament to how robust the technique is (Deem, 2009).  
The alternative technique of using somatic cell nuclear transfer (SCNT) has never been 
accomplished in humans, and would use an embryo anyway, so at this point iPS cells remain our 
best alternative to embryo-derived ES cells (Deem, 2009).  Although it is unlikely, if iPS cells 
were eventually demonstrated to be totipotent, the level of potency that can create a new human 
life, then essentially these induced cells would essentially become cloned human embryos, which 
is illegal in most countries, and their advantage would be negated (Brind’Amour, 2008).  Some 
scientists have shown that mouse iPS cells have the ability to form a new mouse (Boland et al., 
2009) which demonstrates a high level of potency, but most scientists believe iPS cells are at 
least multi-potent.  Some scientists have shown that iPS cells carry DNA mutations relative to 
embryo-derived ES cells, which make them harder to grow and might cause cancer (as was 
shown earlier with the viruses) (Dolgin, 2010).  So the potency of iPS cells is still being 
investigated. 
 
Author Chapter-3 Conclusion      
 In this last section I will weigh in on the ethical concerns addressed in this chapter, and 
share my views.  With respect to embryos, I am not against their use for research.  Unlike so 
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many of the religions that faced this question, I do not believe that an embryo, which is 
essentially a ball of cells the size of the period at the end of this sentence (at the 5-day stage), is a 
living human being, therefore I do not see any problem using embryos for research purposes, 
especially if they are going to be used for the greater good.  With respect to embryo sources, I 
am in favor of using the old discarded IVF embryos that were originally created for reproduction 
purposes, since they are going to be discarded anyway, so why not use them for research 
purposes.  Scientists could gain much knowledge from ES cells derived from IVF embryos, but 
if we destroy them before that happens, we might miss curing some diseases.  With respect to 
creating IVF embryos solely for research purposes, I personally have no problem this, so long as 
the male and female donors provide informed consent.   
With respect to adult stem cells, and whether they should be used in lieu of ES cells, this 
question really comes down to which type is more effective for a particular disease.  Clearly 
adult stem cells have few ethical concerns compared to ES, but ES cells might prove more 
effective at say treating spinal cord injuries than adult neuronal stem cells.  I would say to 
continue the development of adult stem cell therapies, but use ES cells until equal therapies can 
be developed.  As to iPS cells, I am strongly in favor of using these cells, so long as they are as 
effective as ES cells and don’t cause cancer.  These cells have great potential with far fewer 
ethical concerns than ES cells.  Perhaps if adult stem cells and iPS cells were used more 
frequently, religious groups and opponents of stem cell research would help strengthen our 
funding to help pave the way to treat many diseases that affect millions of lives.  
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Chapter-4:  Stem Cell Legalities 
Rebecca Paz 
 
The first successful identification and culture of human embryonic stem cells (hESCs) in 
1998 (Thomson et al., 1998) opened the door to a promising future in regenerative medicine in 
which hESCs could potentially cure many diseases, but the discovery also sparked a political and 
ethical debate that continues to this day concerning the moral and legal status of the human 
embryo, which is destroyed in the process of obtaining hESCs. While one side sees it as a human 
being with all the rights and legal status of a person, the other side sees the embryo as a 
collection of cells that at day-5 lack the capacity to think or feel pain, with no interests or rights 
(Roberston, 2010).  The purpose of this chapter is to discuss the evolution of laws regulating 
embryo research.  Adult stem cells and induced pluripotent stem cells (iPSCs) are not directly 
derived from embryos and are therefore less controversial so will not be included in this chapter.  
 
Historical US Federal Funding of Embryo and hESC Research 
In the United States, the embryo debate has centered on the use of federal funds for 
sponsoring embryo and hESC research.  Few legal restrictions exist for hESC research 
performed with private funding, although their use (or any other cell) in human reproductive 
cloning is banned.  Federal funding is often considered the main way to advance science in the 
early stages of research before the economy is receptive to private funding (Robertson, 2010).  
The Federal funding of embryo or hESC research in the US historically related to politics.  
Below is a brief timeline of the main events that have directly or indirectly affected legal policy 
for the federal funding of hESC research in the United States: 
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1973- Roe v Wade:  The US Supreme Court ruled that a fetus is not a person in terms of 
constitutional rights (Roe v Wade, 1972). 
 
1993 -  William Jefferson Clinton becomes the 42
nd
 President of the United States and signs 
into law the NIH Revitalization Act of 1993, superseding the NIH Interim Guidelines 
banning research on fetal tissue, and creates the NIH Human Embryo Research Panel to 
oversee the ethics of fetal and embryonic research (NIH Guide, 1993). 
 
1994 -  The NIH Human Embryo Research Panel advises Clinton that studies on human 
embryos should be allowed and should receive government funding. President Clinton, in 
response to increasing political pressure, opposes the use of federal funding for the 
creation of embryos for research, but allows the use of federal funding for embryos 
discarded from in vitro fertilization clinics (Clinton Presidential Material, 1994; 
Robertson, 2010). 
 
1995 -  Dickey-Wicker Amendment: US Congress, under Republican control, creates the 
Dickey-Wicker Amendment as a rider to an appropriation bill, banning the use of federal 
money in hESC research (Robertson, 2010). This amendment has been attached to 
several other appropriation bills since then.  The wording for the 2009 bill is as follows: 
SEC. 509. (a)  None of the funds made available in this Act may be used for (1) The 
creation of a human embryo or embryos for research purposes; or (2) research in which a 
human embryo or embryos are destroyed, discarded, or knowingly subjected to risk of 
injury or death greater than that allowed for research on fetuses in utero (Public Law 
No.111-8, 2009). 
  
1998 -  hESC Discovery: James Thomson and colleagues successfully differentiate and culture 
hESCs (Thomson et al., 1998). 
 
1999 -  Harriet Rabb Recommendation:  Rabb, General Counsel of the Department of Health 
and Human Services (HHS), is asked to give advice about the legality of using federal 
funds in hESC research under the Dickey-Wicker amendment.  According to Rabb, “the 
statutory prohibition on the use of funds appropriated to HHS for human embryo research 
would not apply to research utilizing human embryonic pluripotent stem cells because 
such cells are not a human embryo within the statutory definition”.  (Rabb, 1999). 
 
2000 - NIH Guidelines:  The National Institutes of Health (NIH) issues guidelines that 
recommend the federal funding of hESC research (National Institutes of Health 
Guidelines, 2000). 
 
2001 - George W. Bush becomes the 43
rd
 president of the United States.  He orders a review of 
the NIH guidelines and temporarily stops federal funding for hESC research. On August 
9, President Bush announces that federal funding will be limited only to currently 
existing hESC lines, but not for developing any new cell lines (Radio Address, 2001; 
Robertson, 2010). The NIH implements President Bush’s policy (Human Embryonic 
Stem Cell Policy, 2001). 
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2005 -  Stem Cell Research Enhancement Act of 2005:  Congress passes a bill that allows 
federal funding of new stem cell lines, but it is vetoed by President Bush in 2006 (Stem 
Cell Research Enhancement Act, 2005). 
 
 National Academy of Sciences publishes a common set of ethical guidelines for the 
responsible conduct of research using human stem cells. Amendments are added in 2007, 
2008, and 2010 (Guidelines for Human Embryonic Stem Cell Research, 2005). 
 
2007 - Stem Cell Research Enhancement Act of 2007: Congress again passes a bill expanding 
federal funding for human embryonic stem cell research, but again it is vetoed by 
President Bush (Stem Cell Research Enhancement Act, 2007). 
 
2009 -  Barack Obama becomes the 44
th
 president of the US.  On March 9, he signs executive 
order 13505, removing some of the limits on the use of federal funds for hESC research 
(President Barack Obama, 2009).  
 
 Updated NIH Guidelines:  The NIH updates the guidelines, which become effective on 
July 7, 2009 (2009 Guidelines on Human Stem Cell Research, 2011).  
 
 Sherley v Sebelius:  In August 2009, adult stem cell researchers James L. Sherley and 
Theresa Deisher et al. file a lawsuit against the NIH, alleging that the new stem cell 
policy violates the Dickey-Wicker Amendment. (Sherley v Sebelius, 2010). 
 
2010 - Temporary Suspension:  On August 23, “District Judge Royce C. Lamberth, grants the 
plaintiff’s (Sherley) a preliminary injunction barring implementation of the Obama 
Administration’s policy pending the outcome of the court case” (Levine, 2011). In 
response, the NIH temporarily suspends the federal funding of hESC research and files an 
appeal. “…on September 9, the U.S. Court of Appeals for the District of Columbia 
enjoined the preliminary injunction, allowing the NIH to resume funding hESC research” 
(Levine, 2011) 
 
2011 - Removal of Suspension:  “On April 29, 2011, in a two-to-one vote, the U.S. Court of 
Appeals for the D.C. Circuit overruled the lower court decision, vacating the preliminary 
injunction” (Cohen and Adashi, 2011; USCA-DC Opinions, 2011). The case now returns 
to the lower court and a final decision by Judge Lamberth.  In the meantime, the decision 
allows federal funding of hESC research to continue.  
 
 
Current US Federal Policy 
 On March 9, 2009, President Obama made the following statement: “Today, with the 
Executive Order I am about to sign, we will bring the change that so many scientists and 
researchers; doctors and innovators; patients and loved ones have hoped for, and fought for, 
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these past eight years: we will lift the ban on federal funding for promising embryonic stem cell 
research.  We will vigorously support scientists who pursue this research.  And we will aim for 
America to lead the world in the discoveries it one day may yield” (Remarks of the President, 
2009).  Following the public address, President Obama signed Executive Order 13505, Removing 
Barriers to Responsible Scientific Research Involving Human Stem Cells, changing the federal 
policy on hESC funding of the previous administration. During the Bush administration, federal 
funding could only be used on studies using hESC lines derived prior to August 2001.  These 
earlier restrictions had “provided only a few viable cell lines, provided little genetic diversity, 
and had been cultured with mouse feeder cells, which raised the risk of infection and 
contamination” (Robertson, 2010).  Obama’s 2009 executive order states that “the Secretary of 
Health and Human Services (Secretary), through the Director of NIH, may support and conduct 
responsible, scientifically worthy human stem cell research, including human embryonic stem 
cell research, to the extent permitted by law” (President Barack Obama, 2009). 
 In response to Obama’s 2009 stem cell policy, on July 7, 2009, the National Institutes of 
Health (NIH) modified their Guidelines for Human Stem Cell Research Policy.  The following is 
an excerpt: 
“These guidelines are based on the following principles: 
1. Responsible research with hESCs has the potential to improve our 
understanding of human health and illness and discover new ways to prevent 
and/or treat illness. 
 
2. Individuals donating embryos for research purposes should do so freely, with 
voluntary and informed consent.”  The entire guidelines are available at: 
http://stemcells.nih.gov/policy/2009guidelines.html 
 
 In general, federal funding is currently available for research if the hESCs are derived 
from embryos created using in vitro fertilization for reproduction and are no longer needed for 
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that purpose, or are donated voluntarily with adequate informed consent that includes a statement 
declaring that no payments are involved. Research is not eligible for federal funding if it involves 
introducing human embryonic stem cells into non-human primate blastocysts, if it is prohibited 
by the Dickey-Wicker Amendment, or if the hESCs are derived from other sources, including 
somatic nuclear transfer or parthenogenetic embryos. 
 In addition to the NIH guidelines, the National Academy of Sciences published their 
Guidelines for Human Embryonic Stem Cell Research in an effort to provide ethical and 
scientific guidance to privately funded hESC research (Guidelines, 2005). 
 
State Stem Cell Policies 
 In view of the restrictions placed on federal funding for hESC research over the past 
decade, some states created their own specific funding to support this research. Among the states 
encouraging and providing funding for hESC research are: California, Connecticut, Illinois, 
Iowa, Maryland, Massachusetts, New Jersey, and New York. Other states, including Arkansas, 
Indiana, Louisiana, Michigan, North Dakota, and South Dakota, prohibit the creation or 
destruction of human embryos for medical research. The following is a brief description of some 
of the states (listed alphabetically) that provide funding for stem cell research, from the 
“National Conference of State Legislature” (Embryonic and Fetal Research Laws, 2008): 
California: In 2004, California passed Proposition 71 to fund adult and embryonic stem 
cell research. The California Institute of Regenerative Medicine (CIRM) controls 
the program. 
 
Connecticut: Senate Bill 934 provides funding for stem cell research.  
 
Illinois: An executive order created the Illinois Regenerative Medicine Institute (IRMI).  
Funding and a bill allowing stem cell research followed. 
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Maryland:  The Maryland Stem Cell Research Fund provides grants for stem cell 
research. 
 
Massachusetts: The Massachusetts Life Sciences Initiative was signed by Governor 
Deval Patrick in 2008. It allotted $1 billion in state funds over a decade, to be 
used in biotechnology, including stem cell research. The stem cell registry and 
bank are located at the University of Massachusetts Medical School in Worcester 
(Dumcius, 2007; Holden, 2009). 
 
Although Massachusetts has several policies restricting the harvest and use of 
hESCs from the fetus or embryo, these are used in tandem with allotments from 
the state legislature to establish centers designed specifically for research on stem 
cell development. One of these centers is the Stem Cell Biology core at the 
University of Massachusetts, explicitly given support to perform research on stem 
cells. This core is allowed to carry out experimentation on stem cells, as well as 
host a public stem cell “bank” in order to store stem cell strains and tissue from 
which these cells can be harvested. UMass hosts a public institutional review 
board that is available to institutions of fifty members or less that are interested in 
pursuing stem cell research. There are certain restrictions placed upon the core: 
the embryos from which the hESCs are harvested cannot mature past 14 days old 
nor can they be transplanted to a uterine environment or any environment 
designed to simulate those conditions; all research conducted on hESCs must be 
reviewed and approved by a board first (this board being composed of 15 
members with a wide variety of experience in the biological and medical field). 
Cell donation by patients is done through informed consent, and human 
reproductive cloning, cloning with the intent of creating a human being, is 
prohibited state-wide (An Act Enhancing Regenerative Medicine, 2005).  
 
New Jersey:  In 2004, New Jersey became the first state that approved funding for stem 
cell research.  They started the New Jersey Stem Cell Institute and awarded grants 
for stem cell research. 
 
New York:  The Empire State Stem Cell Trust was created in 2007 to support stem cell 
research. A recent study by Karmali and collaborators examined and compared 
some of the state funding programs for hESC research. They observed, “the 
analysis indicates that state funding for stem cell research has grown into a 
substantial enterprise that has provided funding on a scale comparable to the 
NIH” (Karmali et al, 2010). Holden reviewed the current situation of state stem 
cell efforts to fund stem cell research and found that “programs generally seem to 
be holding their own in this uncertain environment - at least for now” (Holden, 
2009).  
 
The Interstate Alliance on Stem Cell Research (IASCR) is an organization 
dedicated to advance stem cell research and promotes interstate collaboration. 
More information is available at: http://www.iascr.org/ 
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International Stem Cell Regulations 
 The attitudes toward hESC research are strongly influenced by religion and culture, and 
vary widely around the world.  Some countries have government policies determining the type of 
research allowed, other countries control stem cell research through limits placed on the use of 
public funding, and still others have no legislation at all. “International and regional policies 
covering this work are complex and in flux. The resulting situations both between and within 
jurisdictions can be termed a 'patchwork of patchworks'” (Caulfield et al., 2009).  The following 
is a brief summary of hESC regulation in some parts of the world (Erik, 2011; Ralston, 2008; 
The Hinxton Group, 2006): 
Africa: South Africa allows hESCs to be derived from IVF embryos and allows 
embryos to be created for solely research (Stem Cell Legislation in South 
Africa, 2011). 
 
North and South America:  Canada permits research on embryos discarded from 
in vitro fertilization, but prohibits creating them for research. Brazil 
permits stem cell research using discarded embryos from in vitro 
fertilization. Mexico does not have a current federal policy governing stem 
cell research.  
 
Asia: China allows the creation of human embryos for research and therapeutic 
purposes. Japan allows stem cell research for therapeutic purposes. 
Singapore permits the use of embryos for therapeutic purposes and is 
known as “Asia’s stem cell center”. The Bioethics and Safety Act in South 
Korea allows leftover embryos to be used for therapeutic research. 
According to the Indian Council of Medical Research, hESC from IVF 
embryos can be used for research, but embryos will not be created for that 
purpose.  
 
Europe:  Countries in the European Union vary widely in their regulation of hESC 
research. Countries that allow hES from super-numerary embryos 
(embryos not used in reproduction) include: Belgium, Czech Republic, 
Denmark, Greece, Spain, Finland, France, Netherlands, Portugal, Sweden 
and the United Kingdom.   
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Several international organizations are attempting to provide guidance on the ethical use 
and regulation of stem cells. Among these are: the Hinxton group, the Interstate Alliance 
(IASCR), the International Society for Stem Cell Research (ISSCR), and the United Nations 
Educational and Scientific Organization. The information can be found on their websites: 
http://www.hinxtongroup.org, http://www.iascr.org/, http://www.isscr.org, http://www.iascr.org/ 
and http://www.idia.net.  
 
Chapter-4 Conclusions 
 The legal regulation of hESC research is strongly influenced by the religious, social, and 
political environments of the specific area. Religious and ethical beliefs mold the opinion of the 
public, which in turn influence politicians and ultimately affect federal and state regulation on 
the subject. In the United States, where the legislation has centered on controlling the use of 
federal funding for hESC research, the past decade has seen so many policy changes that it has 
created “something of a roller coaster” for scientists, according to Aaron D. Levine (Levine, 
2011).  In his paper, published on February 4, 2011, he states that “A survey of U.S. stem cell 
scientists shows that uncertainty following the legal challenge to the Obama Administration’s 
hESC research policy has negative scientific and economic impacts, and affects a range of stem 
cell scientists, not just those working with hESCs”.  These “impacts” range from delaying plans 
to begin projects, to impeding ongoing research, to limiting future funding options (Levine, 
2011).  Thus, stability in policies governing hESC research is essential to advance the science.  
 Previous limitations placed on US federal funding have resulted in some states creating 
their own state-supported programs to support stem cell research. Most of those programs 
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continue to function (Holden, 2009). Regulation of hESC research in the rest of the world is 
highly variable, with no current world wide accepted guidelines available at the time.   
 The future of hESC research is currently unknown.  It will likely be affected by several 
factors, including the results of clinical trials involving hESCs, the success or failure of stem 
cells derived from alternative sources like iPSCs, the funding available, and the regulatory 
policies affecting it.  
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PROJECT CONCLUSIONS 
 
 
 
The authors of this project believe that life starts shortly before birth (not at conception) 
and accept late-term abortions in certain cases, the use of embryonic stem cells (ESCs), and 
therefore the destruction of embryos, is acceptable as long as informed consent is given.  Since 
the harvesting of ESCs in the US tends to rely on reproductive super-numerary embryos from 
fertility clinics and similarly discarded embryos (after the donors have used the embryos they 
wanted), informed consent likely will be provided.  We see no major ethical issues with ESC 
harvesting solely for research purposes, but laws should be put into place to protect potential egg 
donors, for example to allow only a certain number per person per year; to use discarded 
embryos first if possible; and people may never be compelled to donate against their wishes. 
Given the ethical issues of using ESCs, iPS cells and adult stem cells should be used first 
whenever possible.  These latter stem cells are harvested from the body of the patient, and 
therefore have certain advantages over ESCs, including a reduced risk of immune rejection.  
Thus, if these cells are available to treat a particular disease, and have been proven to be 
effective, then iPSCs/ASCs are the preferable choice. 
In terms of stem cell regulations, the authors believe that current policies in countries 
such as China, Singapore, and Japan, are adequate for the current scope of stem cell use in 
research and medicine. These countries allow for the use of super-numerary IVF embryos and 
the creation of embryos for the purpose of research. As for the United States, since the regulation 
of stem cells varies wildly from state to state, progress should focus not on the regulation of the 
use of stem cells, but on the availability of federal funding for research on stem cells, as this 
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large level of funding is required to maintain the US leadership in this technology.  Although 
federal funding of some types of ESC research is currently allowed under Obama, we believe the 
laws should be expanded to allow all ES cell lines to be researched.  Therefore, it is imperative 
that US laws be changed to allow federal funding for all stem cell research. 
 
